Altered thrombus formation in von Willebrand factor deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa

Blood

Volumn 112, Issue 3, 2008, Pages 603-609

  Marx, Isabelle ^a,b   Christophe, Olivier D ^a   Lenting, Peter J ^c   Rupin, Alain ^b   Vallez, Marie Odile ^b   Verbeuren, Tony J ^b   Denis, Cécile V ^a,d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FERRIC CHLORIDE; FIBRILLAR COLLAGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; VON WILLEBRAND FACTOR; COLLAGEN; MUTANT PROTEIN; THROMBIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS; WILD TYPE; ANIMAL; BLEEDING; GENETIC VARIABILITY; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS;

ANIMALS; COLLAGEN; HEMORRHAGE; MICE; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; THROMBOSIS; VARIATION (GENETICS); VON WILLEBRAND FACTOR;

EID: 50949116621     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-142943     Document Type: Article

References (33)

1. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol. 2003;10:142-149.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
3. Romijn RA, Westein E, Bouma B, et al. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem. 2003;278:15035-15039.
4. Matsushita T, Meyer D, Sadler JE. Localization of von Willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-toalanine scanning mutagenesis. J Biol Chem. 2000;275:11044-11049.
5. Beacham DA, Wise RJ, Turci SM, Handin RI. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed mutagenesis. J Biol Chem. 1992; 267:3409-3415.
6. Lankhof H,Wu YP, Vink T, et al. Role of the glycoprotein Ib-bindingA1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor. Blood. 1995;86:1035-1042.
7. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103-2114.
8. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95:9524-9529.
9. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392.
10. Marx I, Lenting PJ, Adler T, Pendu R, Christophe OD, Denis CV. Correction of bleeding symptoms in von Willebrand factor-deficient mice by liverexpressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol. 2008;28:419-424.
11. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6:1258-1266.
12. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 1999;10:1735-1737.
13. Lenting PJ, de Groot PG, De Meyer SF, et al. Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF. Blood. 2007;109:2267-2268.
14. Jumilly AL, Veyradier A, Ribba AS, Meyer D, Girma JP. Selective inactivation of Von Willebrand factor binding to glycoprotein IIb/IIIa and to inhibitor monoclonal antibody 9 by site-directed mutagenesis. Hematol J. 2001;2:180-187.
15. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004; 279:12102-12109.
16. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost. 1999;82:1382-1385.
17. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8:1175-1181.
18. Vicaut E, Montalescot G, Hou X, Stucker O, Teisseire B. Arteriolar vasoconstriction and tachyphylaxis with intraarterial angiotensin II. Microvasc Res. 1989;37:28-41.
19. Ye P, Thompson AR, Sarkar R, et al. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther. 2004;10:117-126.
20. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest. 2007; 117:953-960.
21. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006;107:3902-3906.
22. Nonne C, Lenain N, Hechler B, et al. Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol. 2005;25:1293-1298.
23. Reheman A, Gross P, Yang H, et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost. 2005;3:875-883.
24. Yang H, Reheman A, Chen P, et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost. 2006;4:2230-2237.
25. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005;115:3355-3362.
26. Bowie EJ, Solberg LA, Jr., Fass DN, et al. Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. J Clin Invest. 1986;78:26-30.
27. Nichols TC, Samama CM, Bellinger DA, et al. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A. 1995;92:2455-2459.
28. Roussi J, Samama M, Vaiman M, et al. An experimental model for testing von Willebrand factor function: successful SLA-matched crossed bone marrow transplantations between normal and von Willebrand pigs. Exp Hematol. 1996;24:585-591.
29. Cauwenberghs N, Meiring M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ibblocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000;20:1347-1353.
30. Golino P, Ragni M, Cirillo P, et al. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thromb Haemost. 1995;74:974-979.
31. McGhie AI, McNatt J, Ezov N, et al. Abolition of cyclic flow variations in stenosed, endotheliuminjured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation. 1994;90:2976-2981.
32. Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost. 1998;79:202-210.
33. Wu D, Vanhoorelbeke K, Cauwenberghs N, et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99:3623-3628.